{"id":368466,"date":"2023-12-01T18:56:15","date_gmt":"2023-12-01T23:56:15","guid":{"rendered":"https:\/\/platohealth.ai\/eliot-forster-named-levicept-ceo\/"},"modified":"2023-12-03T18:31:40","modified_gmt":"2023-12-03T23:31:40","slug":"eliot-forster-named-levicept-ceo","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/eliot-forster-named-levicept-ceo\/","title":{"rendered":"Eliot Forster named Levicept CEO","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Plus: Sirnaomics promotes Lebel to CMO and updates from\u00a0 Enavate Sciences<\/a>,\u00a0 Avoro Ventures<\/a>, Eagle, Calliditas, 20Med\u00a0<\/h2>\n

\n By Jeff Cranmer, Executive Editor, and Gunjan Ohri, Data Content Analyst<\/span>\n<\/p>\n

December 1, 2023 11:56 PM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Eliot <\/span>Forster became <\/span>CEO of\u00a0 Levicept Ltd.<\/a><\/b>\u00a0Forster was CEO of F-star Biotechnology Ltd. and Immunocore Holdings plc (NASDAQ:IMCR). He succeeds Simon Westbrook, the U.K.-based chronic pain company\u2019s founder, who will become CSO.<\/p>\n

RNAi therapeutics company Sirnaomics Ltd.<\/a> <\/b>(HKEX:2257) promoted<\/span> Francois Lebel to CMO from SVP for preclinical and clinical development. In his new role, Lebel will oversee clinical development of Phase II program, STP705, for squamous cell carcinoma in situ<\/i>. Before joining the cross-border biotech in July, Lebel was EVP of R&D and CMO of Spectrum Pharmaceuticals Inc.\u00a0…<\/p>\n